PMI appoints Matthew Holman as Vice President of Regulatory Strategy

Sep.20.2022
PMI appoints Matthew Holman as Vice President of Regulatory Strategy
Matthew Holman leaves FDA role to become PMI's US Science Engagement and Regulatory Strategy VP as the company seeks to promote safer nicotine alternatives.

Matthew Holman has left his position at the FDA to become the Vice President of Scientific Engagement and Regulatory Strategy for PMI in the United States.


Of course, considering the tobacco companies are currently facing strict regulations and public scrutiny, these appointments are crucial. Badrul Chowdhury, who has worked at the FDA for over 20 years, has accepted the position of Chief Life Sciences Officer, while Matthew Holman has been appointed as Vice President of Science Engagement and Regulatory Strategy for the tobacco company in the United States.


In recent years, Philip Morris International (PMI) has been making efforts to improve its image and reputation by turning towards the sale of safer nicotine alternatives. Former CEO Andre Catantzopoulos believed that a smokeless future is possible and that achieving a consensus with the government and society is necessary through proper supervision and regulation. He stated that alternative nicotine products can be a part of effective tobacco policy. "Thanks to rapid progress in science and technology, and PMI's firm commitment, these products have now become a reality," he said.


Although current CEO of PMI, Jacek Olczak, has stated that the tobacco company intends to achieve its goal of 50% smoke-free product sales by 2025, he also claims the company is fully capable of replacing cigarettes with safer alternatives. "We have a leading portfolio of traditional and smoke-free tobacco products, an excellent management team, and an agile, efficient, and quick-learning organization. We are fully capable of continuing to succeed in our vision of replacing cigarettes with better alternatives for the benefit of consumers, shareholders, and society," he stated earlier this year, quoted by The Edge.


PMI is working hard to change its image.


Last year, PMI received criticism from the British Asthma Association and British Lung Foundation for their collaboration with asthma inhaler manufacturer Vectura. This move appeared hypocritical, as the investment was in a product that could help treat tobacco-related diseases.


Meanwhile, Altria has recently reiterated its plan to enter the healthcare field, stating that this is a natural evolution for tobacco companies. "This is a natural evolution for PMI to further transform our business into a more holistic lifestyle, consumer health, and healthcare company in the future. This evolution is not only fulfilling our continued commitment to a smoke-free future but also fulfilling the development and commercialization of scientifically validated products and solutions to meet unmet consumer and patient needs.


The market for health and wellness products is vast and constantly expanding. We have several key areas of focus in our pipeline. For consumers and over-the-counter healthcare products, we have several initiatives focused on concentration, sleep, energy, pain relief, and calmness. In the healthcare field, we believe that patients' demand for fast and effective treatments for cardiovascular diseases such as myocardial infarction and neurological conditions such as migraines has yet to be met, and innovative solutions can meet these needs. We recently accelerated this part of our strategy through the acquisition of Vectura, an innovative inhalation delivery solution provider, and Fertin, a leading developer and manufacturer of innovative drugs and healthcare products based on oral and intraoral delivery systems," said Alzack.


Statement:


This article is compiled from third-party information and is intended solely for industry exchange and learning purposes.


This article does not represent the views of 2FIRSTS, and 2FIRSTS cannot confirm the authenticity or accuracy of the article's content. The compilation of this article is solely for communication and research within the industry.


Due to limitations in translation abilities, the translated article may not fully express the original text, so please refer to the original text for accuracy.


2FIRSTS maintains complete alignment with the Chinese government in regards to any statements or positions relating to domestic issues, Hong Kong, Macau, Taiwan, and foreign affairs.


The copyright of the compiled information belongs to the original media and author. If there is any infringement, please contact us for removal.



Disclaimer

This article is provided solely for professional research, industry discussion, and informational purposes. Any references to brands, companies, products, technologies, or policies are made for factual reporting and analytical purposes only, and do not constitute endorsement, recommendation, promotion, or advertising by 2Firsts.

Nicotine-containing products, including but not limited to cigarettes, e-cigarettes, heated tobacco products, and nicotine pouches, carry significant health risks. Readers are responsible for complying with all applicable laws and regulations in their respective jurisdictions, including age restrictions and access limitations.

The information contained in this article should not be regarded as investment, legal, medical, regulatory, or commercial advice. While 2Firsts strives to ensure the accuracy and reliability of its content, it does not assume liability for any direct or indirect loss arising from errors, omissions, inaccuracies, or reliance on the information contained herein.

This article is not intended for individuals below the legal age for accessing tobacco or nicotine-related information in their jurisdiction.

 

Copyright Notice

This article is either original content produced by 2Firsts or content reproduced, translated, summarized, or adapted from third-party sources with attribution where applicable. The intellectual property rights of the original content remain with 2Firsts or the respective original rights holders.

No individual or organization may copy, reproduce, distribute, republish, modify, translate, or otherwise use this content without prior authorization. Any unauthorized use may result in legal action.

For copyright-related inquiries, corrections, or removal requests, please contact: info@2firsts.com.

 

AI-Assisted Translation and Editing Notice

Portions of this article may have been translated, edited, or reviewed with the assistance of artificial intelligence tools to improve efficiency and readability. Due to the limitations of AI-assisted translation and editing, discrepancies, omissions, or inaccuracies may exist when compared with the original source.

Where applicable, readers are advised to refer to the original source for the most complete and accurate information. If you identify any errors or believe that any content infringes upon your rights, please contact us at info@2firsts.com, and we will review and address the matter promptly.

GAO Audit Finds Nearly 132,000 FDA Tobacco Applications Waiting an Average 1,266 Days as Nicotine Pouch Pilot Practices Move Into Vape PMTA Reviews
GAO Audit Finds Nearly 132,000 FDA Tobacco Applications Waiting an Average 1,266 Days as Nicotine Pouch Pilot Practices Move Into Vape PMTA Reviews
A U.S. Government Accountability Office audit found that 131,915 tobacco product applications submitted to the FDA since 2018 remained without a final review as of December 31, 2025, with pending applications waiting an average of 1,266 days. GAO also found FDA lacks the data needed to systematically determine whether scientific reviews meet applicable timelines. HHS agreed to upgrade the agency's tracking systems. At the same time, FDA has begun applying lessons from its nicotine pouch PMTA pilot to e-cigarette reviews, while changes to enforcement policy and electronic submissions are making the specific stage of a PMTA increasingly relevant to market access.
FDA
Oct.03
PMI Pushes Smoke-Free Business in Latin America as Argentina Lifts Heated Tobacco Ban, Mexico City Share Tops 7%
PMI Pushes Smoke-Free Business in Latin America as Argentina Lifts Heated Tobacco Ban, Mexico City Share Tops 7%
Philip Morris International (PMI) showcased IQOS heated tobacco systems and nicotine pouch products at Technovation 2026 in Buenos Aires on October 7–8, presenting research on consumer attitudes, regulatory developments and illicit cigarette trade across Latin America. PMI Chief Global Growth Officer Stefano Volpetti said smoke-free products accounted for more than 7% of the Mexico City market. Argentina repealed its heated tobacco ban in May 2026 and introduced registration requirements for tobacco and nicotine products, while local media reported nicotine pouch sales in Mendoza. A PMI-commissioned survey found that only 8% of respondents across four Latin American countries were familiar with nicotine pouches. A separate KPMG study estimated illicit cigarette consumption at 77 billion sticks across 11 markets in Latin America and Canada in 2025.
PMI
Oct.13
Philip Morris Malaysia Again Meets Religious Authority Over Cigarette Alternatives as Perlis Mufti Responds on Halal Criteria
Philip Morris Malaysia Again Meets Religious Authority Over Cigarette Alternatives as Perlis Mufti Responds on Halal Criteria
Philip Morris Malaysia Managing Director Naeem Shahab Khan met Perlis Mufti Mohd Asri Zainul Abidin on September 17 and presented the company's shift from conventional cigarettes toward alternative products. The mufti said a product could be considered halal if it is clean, its side effects are not harmful or can be controlled, and it does not involve excessive waste. His remarks did not mention IQOS or any other specific PMI product and did not amount to a new product-specific religious ruling. It was at least the second publicly reported engagement between Philip Morris Malaysia and a Malaysian religious institution over cigarette alternatives within six months.
Regulations
Sep.18 by 2Firsts Perspectives
Product | SMOORE's VAPORESSO Introduces VAST Refillable Vape With Three Resistances in One Pod
Product | SMOORE's VAPORESSO Introduces VAST Refillable Vape With Three Resistances in One Pod
SMOORE-owned vaping brand VAPORESSO introduced the VAST refillable open-system vape in October 2026, featuring Tri-Core Mesh technology that integrates three resistance configurations—0.8Ω, 0.6Ω and 0.4Ω—within a single pod. The device supports different operating modes and e-liquid types. The standard version features a 10mL pod, while a TPD-labelled configuration combines a 2mL pod with an 8mL refill container. The device has a 1,600mAh battery and a maximum output of 30W. VAPORESSO claims up to six pod refills and a tested coil lifespan of up to 150,000 puffs. The UK's MHRA published a related device notification on October 12. The official MSRP is $25.90, compared with a $35.90 listing on VAPORESSO's direct store.
product
Oct.30
Japan Survey Finds 49.5% Would Cut Tobacco Use if Prices Rise, 64.6% Show Interest in Nicotine-Free Alternatives
Japan Survey Finds 49.5% Would Cut Tobacco Use if Prices Rise, 64.6% Show Interest in Nicotine-Free Alternatives
A September online survey commissioned by Japanese smoking-accessories company Lightec found that 49.5% of respondents would consider reducing tobacco use if prices rose further, while 25.1% would consider switching to cheaper brands and 14.5% would consider using or combining alternatives such as vapes and nicotine-free herbal sticks. Another 64.6% expressed some level of interest in such alternatives. The survey covered 1,088 respondents aged 20 to 70 and was conducted by a company that sells NICOLESS nicotine-free vaping and herbal-stick products, meaning its findings should not be treated as representative of Japan's smoking population.
DATA
Oct.12
Special Report | From New York to Washington: How FDA’s Tobacco Center Is Reworking Product Review
Special Report | From New York to Washington: How FDA’s Tobacco Center Is Reworking Product Review
FDA’s Center for Tobacco Products is reshaping how it approaches tobacco product review. Based on 2Firsts’ on-site reporting in New York and Washington, this report traces CTP’s emerging direction: stronger links between PMTA and tobacco harm reduction, more category-specific review, greater emphasis on decision-relevant science, more predictable timelines and expanded use of sPMTA for product modifications. CTP also acknowledged major constraints, including just nine PMTA review teams, persistent backlogs and limits on hiring capacity.
Regulations
Oct.08